MedPath

The Impact of Different Relaxation Techniques on Psoriasis Patients With an Elevated Psychological Stress Level

Not Applicable
Recruiting
Conditions
Stress, Psychological
Psoriasis
Depression
Anxiety
Registration Number
NCT05894759
Lead Sponsor
Grigore T. Popa University of Medicine and Pharmacy
Brief Summary

Two mind-relaxing techniques will be applied to psoriasis patients with an elevated psychological stress profile at baseline

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
105
Inclusion Criteria
  • clinical diagnosis of psoriasis
  • adequate psychological stress profile
  • access to a personal computer/ laptop/ smartphone with internet connection
  • agreement to the informed consent form
Exclusion Criteria
  • other dermatological conditions which impair the life quality
  • psychological disorders under psychiatric treatment
  • hearing impairment
  • other on-going medical studies
  • pregnancy
  • aliteracy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Psychological stress6 months

A visual analog scale will be used at baseline, 1 month and 6 months. Analog scale minimum value = 0 (no stress) Analog scale maximum value = 10 (maximum stress)

General Anxiety Disorder-76 months

General Anxiety Disorder-7 questionnaire will be applied at baseline, 1 month and 6 months.

General anxiety disorded-7 minimum score = 0 (no anxiety) General anxiety disorded-7 maximum score = 21 (maximum anxiety)

Patient Health Questionnaire-96 months

Patient Health Questionnaire-9 will be applied at baseline, 1 month and 6 months.

Patient Health Questionnaire-9 minimum score = 0 (no depression) Patient Health Questionnaire-9 maximum score = 27 (maximum depression)

Dermatological Life Quality Index6 months

Dermatological Life Quality Index Score will be calculated at baseline, 1 month and 6 months.

Dermatological Life Quality Index minimum score = 0 (no impairment of life quality) Dermatological Life Quality Index maximum score = 30 (maximum impairment of life quality)

Secondary Outcome Measures
NameTimeMethod
Psoriasis Area and Severity Index6 months

Psoriasis Area and Severity Index score will be calculated will be applied at baseline, 1 month and 6 months.

Psoriasis Area and Severity Index minimum score = 0 (no severity - no lesions) Psoriasis Area and Severity Index maximum score = 72 (maximum severity)

The Revised Illness Perception Questionnaire6 months

The Revised Illness Perception Questionnaire will be applied at baseline, 1 month and 6 months.

The Revised Illness Perception Questionnaire minimum score = 0 (best illness perception) The Revised Illness Perception Questionnaire maximum score = 80 (worst illness perception)

Dermatological treatment compliance6 months

A visual analog scale will be applied at baseline, 1 month and 6 months. Analog scale minimum value = 0 (total lack of compliance) Analog scale maximum value = 10 (maximum compliance)

Self Administered Psoriasis Area and Severity Index6 months

The self Administered Psoriasis Area and Severity Index score will be calculated by the patient at baseline, 1 month and 6 months.

The self Administered Psoriasis Area and Severity Index minimum score = 0 (no severity - no lesions) The self Administered Psoriasis Area and Severity Index maximum score = 72 (maximum severity)

Trial Locations

Locations (1)

Saint Spiridon Emergency Clinical County Hospital- Dermatology department

🇷🇴

Iasi, Romania

Saint Spiridon Emergency Clinical County Hospital- Dermatology department
🇷🇴Iasi, Romania
Bogdan-Marian Tarcau
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.